SER140 - Type 2 Diabetes

Professor Richard E Pratley, MD

Florida Hospital Diabetes Institute, FL, USA

Dr. Pratley is an internationally recognized expert in diabetes and is board certified in internal medicine. He received his medical degree from Wayne State University in Detroit, and completed fellowships in geriatric medicine and gerontology at the University of Michigan, John Hopkins University, and the National Institute on Aging.

As a member of the American Diabetes Association, the European Association for the Study of Diabetes and The Obesity Society, Dr. Pratley continues his active involvement in the professional community. He is a member of the editorial boards of The Lancet: Diabetes and Endocrinology, The Journal of Diabetes and its Complications, the Journal of Clinical Endocrinology and Metabolism, and acts as an ad hoc reviewer for many other journals.

Dr. Pratley regularly presents at national and international meetings, has conducted numerous research studies on the pathogenesis, prevention and treatment of diabetes, and has published over 190 peer-reviewed articles on diabetes. His research interests include the prevention of diabetes, improving the care for older person1s with diabetes, developing new drugs to treat and prevent diabetes and its complications, and understanding the role of the fat cell in increasing the risk of diabetes and heart disease.

Professor Thomas Mandrup-Poulsen, MD, DMSc

Copenhagen University Hospital, Denmark

Thomas Mandrup-Poulsen is a physician scientist, specialist in internal medicine and endocrinology. He is a pioneer in the field of immuno-metabolism with the discovery that inflammatory cytokines impair the function and viability of pancreatic islet b-cells, for which he was awarded the 1994 Minkowski Prize of the EASD.

His research focuses on the mechanisms of action of pro-inflammatory cytokines, metabolites and oxidative stress causing islet cell damage in diabetes and how this can be prevented, employing in silico, in vitro, ex vivo and in vivo studies, animal diabetes models and clinical trials in diabetic patients. He and colleagues conducted the first proof-of-concept clinical trial showing that pro-inflammatory cytokine antagonists improve glycemia and b-cell function in diabetic patients. His expertise covers basic molecular and cellular techniques in b-cell biology, stress signalling, genomics and proteomics, epigenetics, animal models, clinical intervention trials and pharmaco-genomic and biochemical biomarker studies.

Prof. Mandrup-Poulsen has more than 370 publications in high ranking journals (e.g. in Science, Lancet, N Engl J Med, Cell Metabolism, J Clin Invest, Proc Natl Acad Sci USA, J Immunol, J Biol Chem, Diabetes and Diabetologia). He has participated in more than 70 international meetings as invited speaker. In addition, he was Chair of the TRIGR-trial DSMB and has been a member of the Advisory board in several international multicenter clinical studies.